| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $187K | — | — |
| R&D Expense | $1.2M | — | -29.4% |
| SG&A Expense | $1.6M | — | +16.7% |
| Operating Income | -$2.8M | — | +11.5% |
| Net Income | -$2.6M | — | +9.7% |
| EPS (Basic) | -$0.05 | — | +16.7% |
| EPS (Diluted) | -$0.05 | — | +16.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $27.3M | -11.3% | -25.3% |
| Accounts Receivable | $245K | — | — |
| Current Assets | $28.1M | -9.2% | -25.3% |
| Total Assets | $42.7M | -6.4% | -18.6% |
| Current Liabilities | $3.1M | -18.5% | +45.1% |
| Total Liabilities | $3.3M | -17.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$3.5M | — | +8.3% |
| Capital Expenditures | $11K | — | — |
| Investing Cash Flow | -$11K | — | — |
| Free Cash Flow | -$3.5M | — | +8.0% |
| +31.9% |
| Stockholders' Equity | $39.4M | -5.2% | -21.1% |